Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study

  • Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure)
  • The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
  • Arterial stiffness is a noted indicator of diseases such as heart, kidney, and pancreas organ ailments that increase mortality with age, therefore the ability to reduce arterial stiffness may have implications for improving human wellness and longevity
  • HYPER-H21-2 results evidence DehydraTECH-CBD reduces arterial stiffness

Lexaria Bioscience LEXX, an innovator in how drugs are utilized by the human body, is reporting newly found benefits from cannabidiol (“CBD”) enhanced by Lexaria’s patented DehydraTECH(TM) technology.

The company’s Dec. 8 news release notes that DehydraTECH-formulated CBD was found to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) patients volunteering in Lexaria’s HYPER-H21-2 human clinical study (https://cnw.fm/zIrF2). The company believes…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWire: Text “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Image Sourced from Pixabay

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksHealth CareGeneralInvestorBrandNetworkPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...